Category: 41575-94-4

Application In Synthesis of cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II). The mechanism of aromatic electrophilic substitution of aromatic heterocycles is consistent with that of benzene. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR. Author is Kobayashi, Takashi; Ito, Katsuhiro; Kojima, Takahiro; Maruyama, Satoru; Mukai, Shoichiro; Tsutsumi, Masakazu; Miki, Jun; Okuno, Tomoya; Yoshio, Yuko; Matsumoto, Hiroaki; Shimazui, Toru; Segawa, Takehiko; Karashima, Takashi; Masui, Kimihiko; Fukuta, Fumimasa; Tashiro, Kojiro; Imai, Kazuto; Suekane, Shigetaka; Nagasawa, Seiji; Higashi, Shin; Fukui, Tomohiro; Ogawa, Osamu; Kitamura, Hiroshi; Nishiyama, Hiroyuki.

Neutrophil-to-lymphocyte ratio (NLR) was reported to be associated with prognosis of urothelial cancer (UC) patients receiving systemic chemotherapy or immunotherapy. However, it has not been elucidated how preceding first-line chemotherapy affects NLR and subsequent second-line pembrolizumab treatment. This multicenter study analyzed 458 patients with metastatic UC who received first-line chemotherapy and second-line pembrolizumab with regard to pre-chemotherapy and pre-pembrolizumab NLR in association with the efficacy of chemotherapy and pembrolizumab treatment. NLR was increased in 47% while decreased in 53% of patients before and after first-line chemotherapy. High pre-chemotherapy NLR (ge 3) was significantly associated with unfavorable overall (OS, P = 0.0001) and progression-free (P lt 0.0001) survivals after first-line chemotherapy. However, pre-chemotherapy NLR showed only modest influence on radiol. response and survival after second-line pembrolizumab treatment, whereas pre-pembrolizumab NLR showed higher association NLR decrease was associated with partial response or greater objective response by first-line chemotherapy, while NLR increase was associated with higher patient age. In conclusion, immediate pre-chemotherapy and pre-pembrolizumab NLR was significantly associated with efficacy of the following treatment, resp. However, even patients with high pre-chemotherapy NLR achieved favorable OS if they had their NLR reduced by chemotherapy, whereas those with high pre-chemotherapy NLR yielded unfavorable OS if they had their NLR remained high after chemotherapy, suggesting that chemotherapy may have differential effect on the efficacy of subsequent pembrolizumab treatment in UC patients.

There are many compounds similar to this compound(41575-94-4)Application In Synthesis of cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II). if you want to know more, you can check out my other articles. I hope it will help you，maybe you’ll find some useful information.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Name: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II). The protonation of heteroatoms in aromatic heterocycles can be divided into two categories: lone pairs of electrons are in the aromatic ring conjugated system; and lone pairs of electrons do not participate. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about Assessment of quality of life among advanced ovarian cancer patients in a tertiary care hospital in India.. Author is Sarkar, Sinjini; Sahoo, Pranab K; Pal, Ranita; Mistry, Tanuma; Mahata, Sutapa; Chatterjee, Puja; Vernekar, Manisha; Mandal, Syamsundar; Bera, Tanmoy; Nasare, Vilas D.

PURPOSE: The study aims to record the quality of life (Qol) and its changes while ovarian cancer (OC) patients undergo debulking surgeries and chemotherapy in a tertiary care hospital of Eastern India. METHODS: Patients with advanced epithelial OC (FIGO stages III-IV) were recruited. They underwent primary/interval debulking surgeries with classical chemotherapy (adjuvant/neoadjuvant) of intravenous tri-weekly doses of paclitaxel + carboplatin. QoL was assessed using Fact- O + FACIT-Sp-12 questionnaire with a set of 51 questions in different domains (spiritual, physical, social, emotional, and functional factors) and a special set for OC patients under the heading “”Additional concerns.”” The responses from patients were recorded at baseline (diagnosis/study entry), 2, 4, and 6 months during the treatment visits. Overall survival (OS) was assessed using Kaplan Meier curve. RESULTS: A majority of patients were 49.15±10.8 years of age, school-educated (54%), unemployed/homemakers (73.5%), belonging from rural setup (64.6%) with a monthly income of Rs. 2000/- to Rs. 5000/-. There was no statistically significant (p>0.05) improvement found in Qol from the baseline till the end of the study, neither overall nor in subsets (responders (Rs)/partial responders (PRs)/non-responder (NRs) groups or the adjuvant and neoadjuvant chemotherapy groups). The common toxicities like anemia, constipation, and weight loss were significantly (p<0.05) correlated with the patients' physical, functional, emotional, and social well-being. CONCLUSION: Ovarian cancer patients represent a poor functional, social, and disease-specific quality of life that needs to be addressed, identified, and improved by the growing nexus of healthcare providers and researchers. I hope my short article helps more people learn about this compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II))Name: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II). Apart from the compound(41575-94-4), you can read my other articles to know other related compounds.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The reaction of an aromatic heterocycle with a proton is called a protonation. One of articles about this theory is 《Real-world Overall Survival Using Oncology Electronic Health Record Data: Friends of Cancer Research Pilot》. Authors are Lasiter, Laura; Tymejczyk, Olga; Garrett-Mayer, Elizabeth; Baxi, Shrujal; Belli, Andrew J.; Boyd, Marley; Christian, Jennifer B.; Cohen, Aaron B.; Espirito, Janet L.; Hansen, Eric; Sweetnam, Connor; Robert, Nicholas J.; Small, Mackenzie; Stewart, Mark D.; Izano, Monika A.; Wagner, Joseph; Natanzon, Yanina; Rivera, Donna R.; Allen, Jeff.The article about the compound:cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)cas:41575-94-4,SMILESS:O=C1C2(CCC2)C(O[Pt]O1)=O.N.N).Reference of cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II). Through the article, more information about this compound (cas:41575-94-4) is conveyed.

In prior work, Friends of Cancer Research convened multiple data partners to establish standardized definitions for oncol. real-world end points derived from electronic health records (EHRs) and claims data. Here, we assessed the performance of real-world overall survival (rwOS) from data sets sourced from EHRs by evaluating the ability of the end point to reflect expected differences from a previous randomized controlled trial across five data sources, after applying inclusion/exclusion criteria. The KEYNOTE-189 clin. trial protocol of platinum doublet chemotherapy (chemotherapy) vs. programmed cell death protein 1 (PD-1) in combination with platinum doublet chemotherapy (PD-1 combination) in first-line nonsquamous metastatic non-small cell lung cancer guided retrospective cohort selection. The Kaplan-Meier product limit estimator was used to calculate 12-mo rwOS with 95% confidence intervals (CIs) in each data source. Cox proportional hazards models estimated hazard ratios (HRs) and associated 95% CIs, controlled for prognostic factors. Once the inclusion/exclusion criteria were applied, the five resulting data sets included 155 to 1,501 patients in the chemotherapy cohort and 36 to 405 patients in the PD-1 combination cohort. Twelve-month rwOS ranged from 45% to 58% in the chemotherapy cohort and 44% to 68% in the PD-1 combination cohort. The adjusted HR for death ranged from 0.80 (95% CI: 0.69, 0.93) to 1.15 (95% CI: 0.71, 1.85), controlling for age, gender, performance status, and smoking status. This study yielded insights regarding data capture, including ability of real-world data to precisely identify patient populations and the impact of criteria on end points. Sensitivity analyses could elucidate data set-specific factors that drive results.

I hope my short article helps more people learn about this compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II))Reference of cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II). Apart from the compound(41575-94-4), you can read my other articles to know other related compounds.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Category: esters-buliding-blocks. The mechanism of aromatic electrophilic substitution of aromatic heterocycles is consistent with that of benzene. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer. Author is Roy, Sudipta; Whitehead, Timothy D.; Li, Shunqiang; Ademuyiwa, Foluso O.; Wahl, Richard L.; Dehdashti, Farrokh; Shoghi, Kooresh I..

We sought to exploit the heterogeneity afforded by patient-derived tumor xenografts (PDX) to first, optimize and identify robust radiomic features to predict response to therapy in subtype-matched triple neg. breast cancer (TNBC) PDX, and second, to implement PDX-optimized image features in a TNBC co-clin. study to predict response to therapy using machine learning (ML) algorithms. TNBC patients and subtype-matched PDX were recruited into a co-clin. FDG-PET imaging trial to predict response to therapy. One hundred thirty-one imaging features were extracted from PDX and human-segmented tumors. Robust image features were identified based on reproducibility, cross-correlation, and volume independence. A rank importance of predictors using ReliefF was used to identify predictive radiomic features in the preclin. PDX trial in conjunction with ML algorithms: classification and regression tree (CART), Naive Bayes (NB), and support vector machines (SVM). The top four PDX-optimized image features, defined as radiomic signatures (RadSig), from each task were then used to predict or assess response to therapy. Performance of RadSig in predicting/assessing response was compared to SUVmean, SUVmax, and lean body mass-normalized SULpeak measures. Sixty-four out of 131 preclin. imaging features were identified as robust. NB-RadSig performed highest in predicting and assessing response to therapy in the preclin. PDX trial. In the clin. study, the performance of SVM-RadSig and NB-RadSig to predict and assess response was practically identical and superior to SUVmean, SUVmax, and SULpeak measures. We optimized robust FDG-PET radiomic signatures (RadSig) to predict and assess response to therapy in the context of a co-clin. imaging trial.

I hope my short article helps more people learn about this compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II))Category: esters-buliding-blocks. Apart from the compound(41575-94-4), you can read my other articles to know other related compounds.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Related Products of 41575-94-4. The protonation of heteroatoms in aromatic heterocycles can be divided into two categories: lone pairs of electrons are in the aromatic ring conjugated system; and lone pairs of electrons do not participate. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis. Author is Vidra, Radu; Nemes, Adina; Vidrean, Andreea; Pintea, Sebastian; Tintari, Snejeana; Deac, Andrada; Ciuleanu, Tudor.

Meta-anal. of the addition of platinum compounds to standard neoadjuvant chemotherapy (NACT) for triple-neg. breast cancer (TNBC) is highly controversial. Platinum agents, such as cisplatin and carboplatin, are DNA-damaging agents which exhibit activity in breast cancer, particularly in the TNBC subgroup. In order to assess the efficacy of each most representative platinum agent (cisplatin and carboplatin) in patients with TNBC treated with NACT, the present study performed a systematic review and meta-anal. of all available published studies on TNBC. A search of PubMed was performed to identify studies that investigated platinum-based NACT in patients with TNBC. The primary endpoints were the pooled rate of the pathol. complete response (pCR) between cisplatin vs. carboplatin-based NACT. A total of 24 studies were selected (17 studies for carboplatin and 6 studies for cisplatin and 1 study with both carboplatin and cisplatin, with 20 prospective studies) for the anal. of 1,711 patients with TNBC. Overall, the pooled rate of pCR in patients treated with platinum-based NACT was 48%. No significant differences were observed between the rates of pCR obtained under carboplatin vs cisplatin treatment. The carboplatin pCR rate was 0.470 [95% confidence interval (CI), 0.401-0.539], while the cisplatin pCR rate was 0.473 (95% CI, 0.379-0.568). The comparison between these two categories revealed no significant differences (P=0.959). In the whole, the present study demonstrates that neoadjuvant platinum-based chemotherapy improves the pCR rate in patients with TNBC, regardless of the platinum agent used. Carboplatin may thus represent a viable option due to its more favorable toxicity profile.

Here is just a brief introduction to this compound(41575-94-4)Related Products of 41575-94-4, more information about the compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)) is in the article, you can click the link below.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Electric Literature of C6H12N2O4Pt. The protonation of heteroatoms in aromatic heterocycles can be divided into two categories: lone pairs of electrons are in the aromatic ring conjugated system; and lone pairs of electrons do not participate. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about Differences in the Therapeutic Effect of Chemotherapy Regimens for Concurrent Chemoradiotherapy of Locally Advanced Non-small Cell Lung Cancer.. Author is Horiuchi, Minoru; Oguri, Tetsuya; Kagawa, Yusuke; Sone, Kazuki; Fukuda, Satoshi; Uemura, Takehiro; Takakuwa, Osamu; Maeno, Ken; Fukumitsu, Kennsuke; Kanemitsu, Yoshihiro; Tajiri, Tomoko; Ohkubo, Hirotsugu; Takemura, Masaya; Ito, Yutaka; Niimi, Akio.

BACKGROUND/AIM: The optimal chemotherapy for concurrent chemoradiotherapy (cCRT) of lung cancer is still unclear. PATIENTS AND METHODS: We investigated the therapeutic effect of different chemotherapy regimens for cCRT of lung cancer in 65 patients at our hospital. RESULTS: Of the 65 patients, 53 were male and 12 female. The median age was 64 years and 58 participants had a smoking history. The histological type was adenocarcinoma in 34 cases, squamous cell carcinoma in 22 cases, and others in 9 cases. Induction therapy consisted of cisplatin plus vinorelbine (CDDP+VNR) in 50 cases, and weekly carboplatin plus paclitaxel (CBDCA+PTX) in 15 cases. In all patients, the overall response rate, disease control rate, median progression survival, and median overall survival were 78.5%, 95.4%, 337 days, and 1,037 days, respectively. The median progression-free survival was 337 days in total; it was significantly longer for CDDP+VNR than CBDCA+PTX. The median overall survival was 1,037 days in total; it tended to be slightly longer for CDDP+VNR than CBDCA+PTX. CONCLUSION: Different chemotherapy regimens for cCRT possibly have different therapeutic effects.

Here is just a brief introduction to this compound(41575-94-4)Electric Literature of C6H12N2O4Pt, more information about the compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)) is in the article, you can click the link below.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Name: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II). The mechanism of aromatic electrophilic substitution of aromatic heterocycles is consistent with that of benzene. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.. Author is Swisher, Elizabeth M; Aghajanian, Carol; O’Malley, David M; Fleming, Gini F; Kaufmann, Scott H; Levine, Douglas A; Birrer, Michael J; Moore, Kathleen N; Spirtos, Nick M; Shahin, Mark S; Reid, Thomas J; Friedlander, Michael; Steffensen, Karina Dahl; Okamoto, Aikou; Sehgal, Vasudha; Ansell, Peter J; Dinh, Minh H; Bookman, Michael A; Coleman, Robert L.

OBJECTIVE: In the Phase 3 VELIA trial (NCT02470585), PARP inhibitor (PARPi) veliparib was combined with first-line chemotherapy and continued as maintenance for patients with ovarian carcinoma enrolled regardless of chemotherapy response or biomarker status. Here, we report exploratory analyses of the impact of homologous recombination deficient (HRD) or proficient (HRP) status on progression-free survival (PFS) and objective response rates during chemotherapy. METHODS: Women with Stage III-IV ovarian carcinoma were randomized to veliparib-throughout, veliparib-combination-only, or placebo. Stratification factors included timing of surgery and germline BRCA mutation status. HRD status was dichotomized at genomic instability score 33. During combination therapy, CA-125 levels were measured at baseline and each cycle; radiographic responses were assessed every 9 weeks. RESULTS: Of 1140 patients randomized, 742 had BRCA wild type (BRCAwt) tumors (HRP, n = 373; HRD/BRCAwt, n = 329). PFS hazard ratios between veliparib-throughout versus control were similar in both BRCAwt populations (HRD/BRCAwt: 22.9 vs 19.8 months; hazard ratio 0.76; 95% confidence interval [CI] 0.53-1.09; HRP: 15.0 vs 11.5 months; hazard ratio 0.765; 95% CI 0.56-1.04). By Cycle 3, the proportion with ≥90% CA-125 reduction from baseline was higher in those receiving veliparib (pooled arms) versus control (34% vs 23%; P = 0.0004); particularly in BRCAwt and HRP subgroups. Complete response rates among patients with measurable disease after surgery were 24% with veliparib (pooled arms) and 18% with control. CONCLUSIONS: These results potentially broaden opportunities for PARPi utilization among patients who would not qualify for frontline PARPi maintenance based on other trials.

Compound(41575-94-4)Name: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II) received a lot of attention, and I have introduced some compounds in other articles, similar to this compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)), if you are interested, you can check out my other related articles.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The reaction of an aromatic heterocycle with a proton is called a protonation. One of articles about this theory is 《Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150》. Authors are Hopkins, Ashley M.; Kichenadasse, Ganessan; McKinnon, Ross A.; Abuhelwa, Ahmad Y.; Logan, Jessica M.; Badaoui, Sarah; Karapetis, Christos S.; Rowland, Andrew; Sorich, Michael J..The article about the compound:cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)cas:41575-94-4,SMILESS:O=C1C2(CCC2)C(O[Pt]O1)=O.N.N).COA of Formula: C6H12N2O4Pt. Through the article, more information about this compound (cas:41575-94-4) is conveyed.

Abstract: Background: Proton pump inhibitors (PPIs) are commonly used concomitant to cancer treatment and they induce gut microbiota changes. It is increasingly apparent that gut dysbiosis can reduce the effectiveness of immune checkpoint inhibitors (ICI). However, little is known about PPI effects on outcomes with ICIs, particularly in combination, ICI approaches. Methods: Post hoc, Cox proportional hazard anal. of phase III trial, IMpower150 was conducted to assess the association between PPI use and overall survival (OS) and progression-free survival (PFS) in chemotherapy-naive, metastatic non-squamous non-small cell lung cancer participants randomised atezolizumab plus carboplatin plus paclitaxel (ACP), bevacizumab plus carboplatin plus paclitaxel (BCP), or atezolizumab plus BCP (ABCP). PPI use was defined as any PPI administration between 30 days prior and 30 days after treatment initiation. Results: Of 1202 participants, 441 (37%) received a PPI. PPI use was independently associated with worse OS (n = 748; hazard ratio (HR) [95% confidence interval (CI)] = 1.53 [1.21-1.95], P < 0.001) and PFS (1.34 [1.12-1.61], P = 0.002) in the pooled atezolizumab arms (ACP plus ABCP). This association was not apparent for BCP (n = 368; OS 1.01 [0.73-1.39], P = 0.969; PFS 0.97 [0.76-1.25], P = 0.827). The observed OS treatment effect (HR 95% CI) of the atezolizumab (ACP plus ABCP) arms vs BCP was 1.03 (0.77-1.36) for PPI users compared to 0.68 (0.54-0.86) for non-users (P [interaction] = 0.028). A similar association was noted for ABCP vs BCP (PPI users 0.96 [0.68-1.35]; PPI non-users 0.66 [0.50-0.87]; P [interaction] = 0.095). Conclusions: PPI use was a neg. prognostic marker in patients treated with ACP or ABCP, but not BCP. The anal. suggests that PPIs neg. influence the magnitude of ICI efficacy. Compound(41575-94-4)COA of Formula: C6H12N2O4Pt received a lot of attention, and I have introduced some compounds in other articles, similar to this compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)), if you are interested, you can check out my other related articles.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The reaction of an aromatic heterocycle with a proton is called a protonation. One of articles about this theory is 《Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study.》. Authors are Moore, Kathleen N; Chambers, Setsuko K; Hamilton, Erika P; Chen, Lee-May; Oza, Amit M; Ghamande, Sharad A; Konecny, Gottfried E; Plaxe, Steven C; Spitz, Daniel L; Geenen, Jill J J; Troso-Sandoval, Tiffany A; Cragun, Janiel M; Rodrigo Imedio, Esteban; Kumar, Sanjeev; Mugundu, Ganesh M; Lai, Zhongwu; Chmielecki, Juliann; Jones, Suzanne F; Spigel, David R; Cadoo, Karen A.The article about the compound:cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)cas:41575-94-4,SMILESS:O=C1C2(CCC2)C(O[Pt]O1)=O.N.N).SDS of cas: 41575-94-4. Through the article, more information about this compound (cas:41575-94-4) is conveyed.

PURPOSE: This study assessed the efficacy, safety, and pharmacokinetics of adavosertib in combination with four chemotherapy agents commonly used in patients with primary platinum-resistant ovarian cancer. PATIENTS AND METHODS: Women with histologically or cytologically confirmed epithelial ovarian, fallopian tube, or peritoneal cancer with measurable disease were enrolled between January 2015 and January 2018 in this open-label, four-arm, multicenter, phase II study. Patients received adavosertib (oral capsules, 2 days on/5 days off or 3 days on/4 days off) in six cohorts from 175 mg once daily to 225 mg twice daily combined with gemcitabine, paclitaxel, carboplatin, or pegylated liposomal doxorubicin. The primary outcome measurement was overall response rate. RESULTS: Three percent of patients (3/94) had confirmed complete response and 29% (27/94) had confirmed partial response. The response rate was highest with carboplatin plus weekly adavosertib, at 66.7%, with 100% disease control rate, and median progression-free survival of 12.0 months. The longest median duration of response was in the paclitaxel cohort (12.0 months). The most common grade ≥3 adverse events across all cohorts were neutropenia [45/94 (47.9%) patients], anemia [31/94 (33.0%)], thrombocytopenia [30/94 (31.9%)], and diarrhea and vomiting [10/94 (10.6%) each]. CONCLUSIONS: Adavosertib showed preliminary efficacy when combined with chemotherapy. The most promising treatment combination was adavosertib 225 mg twice daily on days 1-3, 8-10, and 15-17 plus carboplatin every 21 days. However, hematologic toxicity was more frequent than would be expected for carboplatin monotherapy, and the combination requires further study to optimize the dose, schedule, and supportive medications.

Compound(41575-94-4)SDS of cas: 41575-94-4 received a lot of attention, and I have introduced some compounds in other articles, similar to this compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)), if you are interested, you can check out my other related articles.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Application of 41575-94-4. The fused heterocycle is formed by combining a benzene ring with a single heterocycle, or two or more single heterocycles. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about The clinical utility of next-generation sequencing for bone and soft tissue sarcoma. Author is Gusho, Charles A.; Weiss, Mia C.; Lee, Linus; Gitelis, Steven; Blank, Alan T.; Wang, Dian; Batus, Marta.

Sarcomas are a rare and heterogeneous tumor group composed of a variety of histol. subtypes. Targeted next-generation sequencing (NGS) of bone and soft tissue sarcomas is a nascent field with limited evidence for its use within clin. practice. Therefore, further research is needed to validate NGS in sarcoma and assess the clin. utility of these techniques with the hope of improving treatment options. Comprehensive mol. profiling with NGS was performed on 136 tumors (116 soft tissue, 20 bone) using two com. vendors. Patient records were retrospectively reviewed, and the clin. impact of NGS-related findings were qual. analyzed to determine actionable mutations and number of changes in treatment. The median age was 55.0 years (IQR 42-67 years), and most patients were non-metastatic at presentation (80.9%, n = 110). Prior to performing NGS, 72.1% (n = 98) were treated with a mean 1.1 ± 1.2 lines of systemic chemotherapy. NGS identified 341 putative alterations with at least one mutation present in 89.7% (n = 122) of samples. In a subset of 111 patients with available TMB data, 78.7% (n = 107) had a low (<6 m/Mb) mutational burden. Among all 136 cases, 47.1% (n = 64) contained clin. actionable alterations, and 12 patients had a change in medical treatment based on NGS. Those who underwent a treatment change all had metastatic or recurrent disease; three of these patients experienced a clin. benefit. Most bone and soft tissue sarcomas harbor at least one genetic alteration, and it appears a sizeable number of tumors contain mutations that are clin. actionable. While a change in treatment based off NGS-related findings occurred in 12 cases, three patients experienced a clin. benefit. Our data provide further proof-of-concept for NGS in sarcoma and suggest a clin. benefit may be observed in select patients. In some applications, this compound(41575-94-4)Application of 41575-94-4 is unique.If you want to know more details about this compound, you can contact with the author or consult more relevant literature.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics